EHP

East Penn Releases New Battery Branding for Electric and Hybrid Vehicles

Retrieved on: 
Wednesday, November 15, 2023

LYON STATION, Pa., Nov. 15, 2023 /PRNewswire-PRWeb/ -- East Penn Manufacturing has announced a new distinction in its line of 12-volt AGM batteries. This new brand helps consumers make a clear choice in a world where vehicle electrification and its complexities are continually evolving. The new distinction of EHP® or Electric Hybrid Performance is designed to clearly indicate which AGM batteries are best suited for electric, hybrid and start-stop 12-volt systems.

Key Points: 
  • East Penn Manufacturing has announced a new distinction in its line of 12-volt AGM batteries for hybrid and electric vehicles.
  • LYON STATION, Pa., Nov. 15, 2023 /PRNewswire-PRWeb/ -- East Penn Manufacturing has announced a new distinction in its line of 12-volt AGM batteries.
  • The new distinction of EHP® or Electric Hybrid Performance is designed to clearly indicate which AGM batteries are best suited for electric, hybrid and start-stop 12-volt systems.
  • Safe, reliable power in any location and a high rate of recyclability helps raise the safety and sustainability profile of electric and hybrid vehicles.

For the Second Year, Capital Rx Ranks Among the Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 8, 2023

179 on the Deloitte Technology Fast 500 ™, which ranks the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

Key Points: 
  • 179 on the Deloitte Technology Fast 500 ™, which ranks the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.
  • 38 out of 87 life sciences companies on this year's list.
  • Demand for modern enterprise health technology - JUDI® - and an aligned PBM model continue to drive Capital Rx's growth.
  • "Each year, we look forward to reviewing the progress and innovations of our Technology Fast 500 winners.

Capital Rx's JUDI® Redefines the Role Technology Plays in the Administration of Medicare, Medicaid, and Commercial Pharmacy Programs

Retrieved on: 
Friday, October 6, 2023

With every core PBM function in JUDI® and the ability to rapidly deploy enhancements, clients save time and money.

Key Points: 
  • With every core PBM function in JUDI® and the ability to rapidly deploy enhancements, clients save time and money.
  • Launched in 2021 to improve costs and service levels in the commercial space, JUDI began processing Medicare claims on January 1, 2023.
  • This is another time-saving workflow enhancement that reduces the potential for errors and alleviates stress for health plan executives.
  • To learn more about Capital Rx's pharmacy benefit administration capabilities and JUDI, please visit Capital Rx – JUDI® .

Enhanced Healthcare Partners Deepens Relationship with Vytalize, Adding on Independent Physician Association of New York and Leading $100 Million Financing Round

Retrieved on: 
Thursday, April 13, 2023

Enhanced Healthcare Partners (“EHP”), a leading private equity firm specializing in transformative, middle-market healthcare businesses, is pleased to announce its portfolio company, Vytalize Health, has acquired a controlling stake in physician-led Independent Physician Association of New York (“IPA NY”), following its recent $100 million equity and debt capital raise led by EHP.

Key Points: 
  • Enhanced Healthcare Partners (“EHP”), a leading private equity firm specializing in transformative, middle-market healthcare businesses, is pleased to announce its portfolio company, Vytalize Health, has acquired a controlling stake in physician-led Independent Physician Association of New York (“IPA NY”), following its recent $100 million equity and debt capital raise led by EHP.
  • Headquartered in Suffolk County, IPA NY is one of the largest multi-specialty IPAs in the country, with more than 3,000 providers.
  • Vytalize is a leading value-based care platform created to help independent physicians and practices improve patient care and lower costs through evidence-based, data-driven medicine.
  • “One year into our partnership, Vytalize has seen exceptional growth in its care delivery infrastructure and geographical presence,” commented EHP General Partner Samarth Chandra.

Mark Farrah Associates Analyzes Trends in Health Insurer Shifts from Commercial to Government Business

Retrieved on: 
Thursday, April 6, 2023

Mark Farrah Associates (MFA), www.markfarrah.com , previously noted health insurance enrollment shifting from commercial risk to government business.

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com , previously noted health insurance enrollment shifting from commercial risk to government business.
  • In a newly released Business Strategy report, using data gleaned from MFA’s 5500 Employer Health Plus and other products, it highlights two carriers, Fallon Health Group and Humana.
  • Both entities have announced plans to transition away from Commercial business to focus more on Government business lines.
  • In March of 2021, Fallon Health Group was one of the first carriers to announce a shift to predominately focus on government programs.

Janus Receives Strategic Growth Investment from Enhanced Healthcare Partners to Accelerate Growth and Fuel Innovation

Retrieved on: 
Tuesday, March 21, 2023

CHICAGO, March 21, 2023 /PRNewswire/ -- Janus, a leading provider of healthcare revenue cycle management (RCM) technology, announced it has received a strategic growth investment from Enhanced Healthcare Partners (EHP), a leading private equity firm specializing in transformative, middle-market healthcare businesses.

Key Points: 
  • CHICAGO, March 21, 2023 /PRNewswire/ -- Janus, a leading provider of healthcare revenue cycle management (RCM) technology, announced it has received a strategic growth investment from Enhanced Healthcare Partners (EHP), a leading private equity firm specializing in transformative, middle-market healthcare businesses.
  • Janus, a leading provider of healthcare revenue cycle management (RCM) technology, receives a new strategic investment.
  • "This investment allows us to accelerate the development of our innovative revenue cycle platform, enabling revenue cycle teams to operate more efficiently and effectively."
  • "Janus is transforming the way health systems are dealing with revenue cycle management," said Won Park, partner at Enhanced Healthcare Partners, who will join Janus' Board of Directors.

Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial

Retrieved on: 
Wednesday, January 11, 2023

The SRC is comprised of two physicians, one independent and the other the principal investigator in the trial.

Key Points: 
  • The SRC is comprised of two physicians, one independent and the other the principal investigator in the trial.
  • This SSc Phase 2a trial is a double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of EHP-101 in patients with SSc.
  • EHP has completed the first two cohorts, each with nine SSc patients, administering two doses either once daily or twice daily.
  • The Company applied for this amendment to create a pathway to possibly advance directly into a Phase 3 clinical trial of EHP-101 in patients suffering from SSc once the Phase 2a trial is completed, rather than first conducting a Phase 2b before continuing to a Phase 3 trial.

Daryl Ludlow Joins JTEC Energy Technical Advisory Board

Retrieved on: 
Thursday, December 22, 2022

ATLANTA, Dec. 22, 2022 /PRNewswire/ -- JTEC Energy, Inc. announced that Daryl Ludlow has joined its Technical Advisory Board.

Key Points: 
  • ATLANTA, Dec. 22, 2022 /PRNewswire/ -- JTEC Energy, Inc. announced that Daryl Ludlow has joined its Technical Advisory Board.
  • JTEC Energy was formed in 2020 to finish development and commercialize the JTEC device, a cleantech energy invention by Dr. Lonnie Johnson that converts waste heat into electricity more efficiently than any machine in history.
  • "Daryl Ludlow has established himself as one of the foremost hydrogen experts," said JTEC CEO Mike McQuary.
  • Led by Mike McQuary, JTEC Energy was spun off from Johnson Research & Development to fully develop and commercialize the JTEC device.

Capital Rx is Crowned Winner of the Fierce Healthcare Fierce Innovation Award

Retrieved on: 
Tuesday, November 15, 2022

Capital Rx wins the Fierce Innovation Award for the Financial/Operational Solutions category.

Key Points: 
  • Capital Rx wins the Fierce Innovation Award for the Financial/Operational Solutions category.
  • NEW YORK, Nov. 15, 2022 /PRNewswire/ -- Capital Rx, a healthcare technology company changing the way prescription drugs are priced and patients are serviced, today announced that it has won the Fierce Healthcare Fierce Innovation Award.
  • The healthcare awards program recognized Capital Rx for JUDI, its ground-breaking enterprise health platform (EHP) for pharmacy benefit administration.
  • Capital Rx won in the Financial/Operational Solutions category for the Fierce Innovation Award.

Emerald Health Pharmaceuticals Reports Data Showing Novel Drug Candidate is First-in-class B55α/PP2A Activator

Retrieved on: 
Thursday, October 13, 2022

SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis (SSc) and multiple sclerosis (MS).

Key Points: 
  • This first-in-class activator of the HIF pathway via modulation of B55a provides a new mechanism to treat diseases where vascular integrity is compromised.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
  • The Companys second product candidate, EHP-102, is in non-clinical development withIND-enabling studiesand is focused on treating Parkinsons disease and Huntingtons disease.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA